Conference Coverage
about 2 hours ago
Upfront MRI Staging Improves Bladder Cancer-Specific Survivalabout 2 hours ago
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLCTrending on CancerNetwork
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
Latest News
Shorts










Podcasts

Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML
Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Diving Into the Practical Applications of ctDNA in Oncology Care
Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

How to Discuss Death: A Conversation of Mortality in Cancer Care
Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Episode 14: Multidisciplinary Care Insights Across World GU 2025
Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Elevating Community Oncology Care: Insights From World GU 2025
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025
Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.
Videos
Continuing Medical Education
All News

Using multiparametric MRI for initial staging, then cystoscopic biopsy, improves bladder cancer-specific survival compared with transurethral resection of bladder tumor staging.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Updated safety findings may support the ARASAFE regimen as a potential standard of care in metastatic hormone-sensitive prostate cancer.

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.

The safety profile of the atezolizumab with Bacillus Calmette-Guérin in NMIBC was consistent with that of each individual agent.

Proactive disclosure of information by clinical social workers in oncology may help equip patients to handle difficult aspects of cancer treatment.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.

A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.

Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.

Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.

Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.

An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.

Whereas CAR T-cell therapies need weeks to be engineered, bispecific therapies can be ready much quicker for patients with progressing non-Hodgkin lymphoma.

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

A median OS of 21.3 months was found in the phase 1/1b trial evaluating ficerafusp alfa plus pembrolizumab in those with metastatic and recurrent HNSCC.

Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.